Literature DB >> 24689102

Benefits of curing hepatitis C infection.

Rui T Marinho1, Sofia Vitor2, Jose Velosa2.   

Abstract

The hepatitis C virus (HCV) infection is one of the most important chronic viral infections worldwide and affects 3% of the world population, approximately 170-200 million people. The consequences of chronic infection are liver cirrhosis and hepatocellular carcinoma, which develop in 20-30% of the patients, leading to hepatic failure, need for liver transplantation and death. The hepatitis C virus is a RNA virus that is prevalent worldwide and is classified by the World Health Organization (International Agency for Research on Cancer) as one of the six oncogenic viruses. Hepatocellular carcinoma is one of the most important cancers and is fifth worldwide, but third in men in terms of mortality. Hepatitis C kills approximately 350,000 people every year, surpassing HIV infection in many countries as a cause of death. Hepatitis C virus can kill in different ways: it can cause cirrhosis, cancer or severe liver disease in people co-infected with HIV. Hepatitis C treatment started in the mid 1980s with a 6% efficacy rate among patients taking thrice-weekly injections of human interferon. This therapy had numerous side effects. The efficacy of hepatitis C treatment has increased, and currently, the efficacy of the so-called direct antiviral agents (DAAs) is 80-90%. The benefits of a cure are enormous and include a lifetime negative serum HCV RNA, disappearance of HCV in the liver, regression of cirrhosis, decreased risk of developing hepatocellular carcinoma, disappearance of oesophageal varices, no more risk of HCV transmission to sexual partners or children, and increased survival. At present, hepatitis C can be considered a curable disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24689102

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  7 in total

1.  Health-Related Quality of Life in Portuguese Patients with Chronic Hepatitis C.

Authors:  Andreia Rei; Marta Rocha; Isabel Pedroto
Journal:  GE Port J Gastroenterol       Date:  2016-12-03

2.  Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Authors:  Abolghasem Asadi-Saghandi; Ali Shams; Gilda Eslami; Seyed Ali Mirghanizadeh; Ebrahim Eskandari-Nasab
Journal:  Virusdisease       Date:  2016-09-28

3.  Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City.

Authors:  Miranda S Moore; Angelica Bocour
Journal:  Public Health Rep       Date:  2021-10-25       Impact factor: 3.117

4.  Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.

Authors:  Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

5.  Burden of Liver Cirrhosis in Portugal between 2010 and 2017.

Authors:  João Manuel Silva; Mário Jorge Silva; Filipe Calinas; Paulo Jorge Nogueira
Journal:  GE Port J Gastroenterol       Date:  2020-10-19

6.  Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data.

Authors:  Michael R Kraus; Henning Kleine; Stefanie Thönnes; Marc Pignot; Yuri Sanchez Gonzalez
Journal:  Infect Dis Ther       Date:  2018-06-19

7.  Hepatitis C direct-acting antiviral outcomes in patients 75 years and older.

Authors:  Parmvir Parmar; Stephen D Shafran; Sergio M Borgia; Karen Doucette; Curtis L Cooper
Journal:  JGH Open       Date:  2020-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.